Last updated on March 2019

B/F/TAF FDC in HIV-1 Infected Virologically Suppressed Adolescents and Children

Brief description of study

The primary objectives of this study are to evaluate the steady state pharmacokinetics (PK) for bictegravir (GS-9883) and confirm the dose of bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy; B/F/TAF) fixed-dose combination (FDC) in HIV-1 infected, virologically suppressed adolescents (12 to < 18 years of age) and children (6 to < 12 years of age). This study will also evaluate the safety and tolerability of B/F/TAF FDC through Week 24 in HIV-1 infected, virologically suppressed adolescents and children.

Clinical Study Identifier: NCT02881320

Contact Investigators or Research Sites near you

Start Over

Pretoria, South Africa
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.